Company Analysis Arrowhead Pharmaceuticals, Inc.
1. Summary
Advantages
- Price (31.66 $) is less than fair price (39.04 $)
- The stock's return over the last year (32.25%) is higher than the sector average (-22.52%).
Disadvantages
- Dividends (0%) are below the sector average (1.35%).
- Current debt level 44.79% has increased over 5 years from 0%.
- The company's current efficiency (ROE=-262.48%) is lower than the sector average (ROE=-73.5%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Arrowhead Pharmaceuticals, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 3.2% | -1% | 0.6% |
| 90 days | 96.9% | -1.7% | 8.5% |
| 1 year | 32.2% | -22.5% | 16.7% |
ARWR vs Sector: Arrowhead Pharmaceuticals, Inc. has outperformed the "Healthcare" sector by 54.76% over the past year.
ARWR vs Market: Arrowhead Pharmaceuticals, Inc. has outperformed the market by 15.51% over the past year.
Slightly volatile price: ARWR is more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical deviations of about +/- 5-15% per week.
Long period: ARWR with weekly volatility of 0.6201% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (31.66 $) is lower than the fair price (39.04 $).
Price significantly below the fair price: The current price (31.66 $) is 23.3% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (-3.56) is lower than that of the sector as a whole (27.88).
P/E vs Market: The company's P/E (-3.56) is lower than that of the market as a whole (51.17).
4.3. P/BV
P/BV vs Sector: The company's P/BV (12.14) is higher than that of the sector as a whole (10.49).
P/BV vs Market: The company's P/BV (12.14) is lower than that of the market as a whole (18.07).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (653.4) is higher than that of the sector as a whole (4.13).
P/S vs Market: The company's P/S indicator (653.4) is higher than that of the market as a whole (27.88).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-4.86) is lower than that of the sector as a whole (18.07).
EV/Ebitda vs Market: The company's EV/Ebitda (-4.86) is lower than that of the market as a whole (36.67).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 121.72% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (121.72%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (0.1902%).
5.4. ROE
ROE vs Sector: The company's ROE (-262.48%) is lower than that of the sector as a whole (-73.5%).
ROE vs Market: The company's ROE (-262.48%) is lower than that of the market as a whole (34.36%).
5.5. ROA
ROA vs Sector: The company's ROA (-62.93%) is lower than that of the sector as a whole (6.82%).
ROA vs Market: The company's ROA (-62.93%) is lower than that of the market as a whole (11.31%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (21.56%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (9.96%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.35%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
